Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer
A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors
Sponsor: National Cancer Institute (NCI)
Listed as NCT00641303, this NA trial focuses on Anxiety Disorder and Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 9 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2023 — Jul 2024 [monthly]
Completed NA
Phase: PHASE2 → NA
-
Mar 2022 — Jun 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .